52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Olympus Corp - To Retire Treasury Shares Worth 5.22% Of Outstanding Stock On June 4
Olympus Corp - Acquisition Of Quest Photonic Devices B.V. In Netherlands
Olympus Says It Will Buy Veran Medical Technologies For $300 Mln
Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, science, video and other products. The Company operates in five business segments. The Endoscopy segment provides gastrointestinal endoscopy, surgical endoscopy, endoscopy systems and repair services. The Therapeutic Equipment segment provides endoscopic treatment tools, energy devices, urology, gynecology and otolaryngology products. The Scientific segment provides biological microscope, industrial microscope, industrial endoscope and non-destructive inspection equipment. The Imaging segment provides digital cameras and recording machines. The Others segment is engaged in the manufacture and sale of biomaterials. The Company is also engaged in the financial investment business.
Medical Equipment & Supplies
Shinjuku Monolith, 2-3-1, Nishi-Shinjuku
President, Chief Executive Officer, Representative Executive Officer, Chairman of Subsidiary, Director
Chief Financial Officer, Executive Officer
Chief Operating Officer, Executive Officer, Chief Executive Officer of Subsidiary
Executive Officer, Chief Technology Officer
Chief Administrative Officer, Executive Officer, Director
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Yasuo Takeuchi remembers the horror he felt in 2017 when, as chief financial officer of Japan's Olympus Corp, he was told an activist investor had taken a stake in the company: the barbarians were at the gate.
Japanese chip and display materials maker JSR Corp said on Monday it will nominate a partner of activist investor ValueAct Capital to be an external board director, a rare move in the country where activists are still viewed with suspicion by many.
Royal Dutch Shell Plc on Sunday said production is being curtailed at its Olympus oil and natural gas platform in the Gulf of Mexico to prepare for potential impacts from Tropical Storm Sally.
Japan's Olympus Corp said on Wednesday it had agreed to sell its loss-making camera business dating back 84 years to Japan Industrial Partners Inc.
* OLYMPUS CORP - TO POSTPONE ANNOUNCEMENT OF FINANCIAL FORECASTS FOR FY2020/21ORIGINALLY SCHEDULED FOR JUNE 24
* UROGEN ANNOUNCES POSITIVE DATA FROM PIVOTAL OLYMPUS TRIAL EVALUATING JELMYTO™ IN PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Sony Corp <6758.T> is selling its 5% stake in Olympus Corp <7733.T> back to the Japanese medical equipment maker for 80.4 billion yen ($762.88 million), a move that Daniel Loeb's activist hedge fund Third Point LLC had called for.
Japanese endoscope maker Olympus Corp said on Thursday it will buy back 68.9 million shares, or a 5.03% stake, from Sony Corp.
A former executive of a subsidiary of Japan's Olympus Corp avoided prison on Wednesday after admitting he failed to file necessary reports with U.S. regulators about infections linked to a widely-used type of medical scope it made.
The former CEO of Olympus, who blew the whistle on a $1.7 billion accounting scandal at the Japanese medical equipment maker in 2011, has won a London court battle over alleged wrongdoing linked to his 64-million-pound ($85-million) pension.
Japan's Olympus Corp <7733.T> said it would propose to give top shareholder U.S. hedge fund ValueAct Capital a seat at its board, a rare move in the country where activists are still viewed by companies as asset-strippers to be resisted.
* Olympus surges after two brokerages raise their stock ratings
* Olympus jumps after two brokerages raise their stock ratings
An Olympus Corp subsidiary pleaded guilty on Monday and agreed to pay $85 million to resolve charges that it failed to file reports with U.S. regulators regarding infections connected to its duodenoscopes while continuing to sell the medical devices used to view the gastrointestinal...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.